Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection
Launched by WOMEN AND INFANTS HOSPITAL OF RHODE ISLAND · Apr 23, 2025
Trial Information
Current as of July 04, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective two different medications are in preventing urinary tract infections (UTIs) after women receive BOTOX-A injections for overactive bladder (OAB). The study will involve women aged 18 and older who are scheduled to have these BOTOX-A injections. Participants will be randomly assigned to receive either methenamine hippurate, a medication that helps prevent UTIs, or a routine antibiotic. The main goal is to see which medication results in fewer UTIs within 30 days after the procedure. Additionally, the trial will also evaluate how satisfied participants are with the medication they receive.
To be eligible for this trial, women must be 18 years or older and be preparing for BOTOX-A injections for OAB. However, certain individuals will not be able to participate, such as those with specific bladder issues, allergies to methenamine hippurate, or those who are currently on antibiotics. If you are interested in potentially joining this study, you can expect to be closely monitored after your procedure to see how well the medication works in preventing infections. It's important to note that this trial has not started recruiting participants yet, but it aims to provide valuable information for improving care for women with OAB.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age or older
- • undergoing intradetrusor BOTOX-A injections in the office setting for overactive bladder
- Exclusion Criteria:
- • cisgender male individuals
- • neurogenic reasons for bladder symptoms (i.e. spinal cord injury, multiple sclerosis, etc.)
- • known allergy and/or contraindication to methenamine hippurate
- • currently already taking methenamine hippurate at the time of the procedure
- • taking antibiotics for any reason on the day of their BOTOX-A procedure
- • positive UTI at time of procedure (positive dip at time of procedure)
- • history of bladder cancer
- • history of pelvic radiation
- • surgically altered detrusor muscle
- • pre-procedural need for catheterization
- • diagnosis of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
- • pregnant or lactating individuals
About Women And Infants Hospital Of Rhode Island
Women & Infants Hospital of Rhode Island is a leading healthcare facility dedicated to the comprehensive care of women and infants, with a strong focus on research and clinical trials aimed at advancing maternal and neonatal health. As a prominent academic medical center affiliated with Brown University, the hospital leverages its expertise in obstetrics, gynecology, and pediatrics to conduct innovative clinical trials that address critical health issues facing women and infants. Committed to improving patient outcomes through evidence-based practices, Women & Infants Hospital fosters a collaborative environment that encourages the integration of cutting-edge research into clinical care, ultimately enhancing the quality of life for its patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Providence, Rhode Island, United States
Patients applied
Trial Officials
Vivian Sung, MD, MPH
Principal Investigator
Women & Infants Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported